arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Caris Life Sciences, Inc.

CAI
$31.65 ▲ +0.18 (+0.57%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
12 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

Caris Life Sciences, Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $9.0B
Dividend Yield —
Revenue Growth 45.4% ↘
Op. Margin 10.2% ↗
ROIC 2.8% ↗
FCF / Share $0.10 ↗
Trailing P/E —
Price / Book 15.1x
FCF Yield 0.3%
Debt / Equity 0.66
info Valuation on last close. End-of-day price, Sep 23, 2026.

12-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$263.71M
↑ +45.4% —
Net Income Profit after all expenses
$-637.00K
↑ +99.1% —
Operating Margin Operating profit as % of sales
10.2%
↑ +317.9% 44th
FCF / Share Free cash flow per share
$0.10
↑ +26.2% —
Long-Term Debt Long-term obligations
$392.69M
↑ +3.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
39
Returns
33
Financial Health
47
Cash Quality
10

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 4 years · 12 quarters